New drug combo targets rare, aggressive cancer in early trial
NCT ID NCT06132113
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 4 times
Summary
This early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). The main goals are to find a safe dose and see if the combination helps shrink tumors. Participants receive infusions of the drug plus chemo for up to 3 years if they benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 764532 (Obrixtamig) plus platinum-based chemotherapy (carboplatin or cisplatin) and etoposide
- What this could lead to
- If it works, this could point toward a new treatment option for advanced neuroendocrine carcinoma, a rare and aggressive cancer.
- What could go wrong
- This is an early Phase 1 trial with only 55 participants, so safety and dosing are the main focus. The combination may cause significant side effects, and it is too early to know if it will improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Aichi, Nagoya, 464-8681, Japan
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hôpital Louis Pradel
Bron, 69500, France
-
INS Paoli-Calmettes
Marseille, 13009, France
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Klinikum der Universität München AÖR
München, 81377, Germany
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Osaka International Cancer Institute
Osaka, Osaka, 541-8567, Japan
-
Sahlgrenska Universitetsjukhuset
Gothenburg, 413 46, Sweden
-
Universitair Medisch Centrum Groningen
Groningen, 9713 GZ, Netherlands
-
Universitair Ziekenhuis Antwerpen
Edegem, 2650, Belgium
-
University of Miami
Miami, Florida, 33136, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
-
Uppsala University Hospital
Uppsala, 751 85, Sweden
-
Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple-Drug cocktail takes aim at rare, aggressive cancers
- Engineered immune cells take aim at deadly lung cancer
- New PET scan shows promise for detecting rare tumors
- New drug combo aimed at tough cancers pulled before starting
- New drug shows promise for rare gut and lung tumors
- New imaging trial peers inside tumors to track experimental Drug's path